Polymers for drug eluting stents

Current Pharmaceutical Design

Volumn 16, Issue 36, 2010, Pages 3978-3988

  Parker, Ted ^a,b   Davé, Vipul ^a,b   Falotico, Robert ^a,b  

^a Department of Medical Affairs and Health Ecomomics Worldwide   (United States)

^b Endovascular Division   (United States)

Author keywords

Bioabsorbable; Biostable; Drug delivery; Drug eluting stent (DES); Local drug delivery; Stent

Indexed keywords

COPOLYMER; ETHYLENE VINYL ACETATE COPOLYMER; EVEROLIMUS; PACLITAXEL; PHOSPHORYLCHOLINE; POLYBUTYLENE METHACRYLATE; POLYHEXYL METHACRYLATE VINYLPYRROLIDONE VINYL ACETATE COPOLYMER; POLYMER; POLYSTYRENE BLOCK ISOBUTYLENE BLOCK STYRENE; POLYVINYLIDENE FLUORIDE; POLYVINYLIDENE FLUORIDE CO HEXAFLUOROPROPYLE; POLYVINYLIDENE FLUORIDE HEXAFLUOROPROPYLENE COPOLYMER; POVIDONE; RAPAMYCIN; UNCLASSIFIED DRUG; ZOTAROLIMUS;

ARTICLE; BARE METAL STENT; BIOCOMPATIBILITY; BIODEGRADABLE IMPLANT; CHEMICAL STRUCTURE; CONTROLLED DRUG RELEASE; CORONARY STENT; DRUG COATING; DRUG ELUTING STENT; ELUTION; HUMAN; NONHUMAN; PRIORITY JOURNAL; RESTENOSIS; STRUCTURE ANALYSIS; VASCULAR TISSUE;

BIOCOMPATIBLE MATERIALS; HUMANS; PHARMACEUTICAL PREPARATIONS; POLYMERS; STENTS;

EID: 79952686031     PISSN: 13816128     EISSN: None     Source Type: Journal    
DOI: 10.2174/138161210794454897     Document Type: Article

References (100)

1. Morice MC, Serruys PW, Sousa JE, et al. A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization. N Engl J Med 2002; 346(23): 1773-80.
2. Carlsson J, James SK, Lindback J, et al. Outcome of drug-eluting versus bare-metal stenting used according to on- and off-label criteria. J Am Coll Cardiol 2009; 53(16): 1389-98.
3. Kukreja N, Onuma Y, Daemen J, Serruys PW. The future of drug-eluting stents. Pharmacol Res 2008; 57(3): 171-80.
4. Ellis SG. A generation 2.5 drug-eluting stent? JACC Cardiovasc Interv 2009; 2(10): 986-8.
5. Wessely R. New drug-eluting stent concepts. Nat Rev Cardiol 2010; 7(4): 194-203.
6. Heldman AW, Cheng L, Jenkins GM, et al. Paclitaxel stent coating inhibits neointimal hyperplasia at 4 weeks in a porcine model of coronary restenosis. Circulation 2001; 103(18): 2289-95.
7. Lansky AJ, Costa RA, Mintz GS, et al. Non-polymer-based pacli-taxel-coated coronary stents for the treatment of patients with de novo coronary lesions: angiographic follow-up of the DELIVER clinical trial. Circulation 2004; 109(16): 1948-54.
8. Hiatt BL, Carter AJ, Yeung AC. The drug-eluting stent: is it the Holy Grail? Rev Cardiovasc Med 2001; 2(4): 190-196.
9. Nakayama Y, Nishi S, Ueda-Ishibashi H, Matsuda T. Fabrication of micropored elastomeric film-covered stents and acute-phase performances. J Biomed Mater Res A 2003; 64(1): 52-61.
10. Kuehler M, De Scheerder I. Drug delivery coatings. USA: Taylor & Francis 2003.
11. Shen WX. Controlled drug delivery systems. Lancaster, Pennsylvania: Technomic Publishing Co. 1996.
12. Pre-market approval P020026 (FDA): Summary of safety and effectiveness data (SSED). Cypher™ Sirolimus OTW &RxCSS. 2003.
13. Caixeta A, Leon MB, Lansky AJ, et al. 5-year clinical outcomes after sirolimus-eluting stent implantation insights from a patient-level pooled analysis of 4 randomized trials comparing sirolimus-eluting stents with bare-metal stents. J Am Coll Cardiol 2009; 54(10): 894-902.
14. Wolf KV, Zong Z, Meng J, et al. An investigation of adhesion in drug-eluting stent layers. J Biomed Mater Res A 2008; 87(1): 272-81.
15. Weisz G, Leon MB, Holmes DR, Jr., et al. Five-year follow-up after sirolimus-eluting stent implantation results of the SIRIUS (Sirolimus-Eluting Stent in De-Novo Native Coronary Lesions) Trial. J Am Coll Cardiol 2009; 53(17): 1488-97.
16. Pinchuk L, Wilson GJ, Barry JJ, Schoephoerster RT, Parel JM, Kennedy JP. Medical applications of poly(styrene-block-isobutylene-block-styrene) (SIBS). Biomaterials 2008; 29(4): 448-60.
17. Puskas JE, Kaszas G. Polyisobutylene-based thermoplastic elastomers: a review. Rubber Chem Technol 1996; 69: 462-75.
18. Puskas JE, Kaszas G. Blends of butyl and bromobutyl rubbers and polystyrene-polyisobutylene-polystyrene (PS-PIBS-PS) block co-polymers with improved processability and physical properties. Rubber Chem Technol 2001; 74: 583-600.
19. Ranade SV, Miller KM, Richard RE, Chan AK, Allen MJ, Helmus MN. Physical characterization of controlled release of paclitaxel from the TAXUS Express2 drug-eluting stent. J Biomed Mater Res A 2004; 71(4): 625-34.
20. Colombo A, Drzewiecki J, Banning A, et al. Randomized study to assess the effectiveness of slow- and moderate-release polymer-based paclitaxel-eluting stents for coronary artery lesions. Circulation 2003; 108(7): 788-94.
21. Kamath KR, Barry JJ, Miller KM. The Taxus drug-eluting stent: a new paradigm in controlled drug delivery. Adv Drug Deliv Rev 2006; 58(3): 412-36.
22. Puskas JE, Antony P, Kontipoulou M. Study of the surface morphology of polyisobutylene-based block copolymers by atomic force microscopy. Macromol Sympos 2002; 183(1): 191-8.
23. Ranade SV, Richard RE, Helmus MN. Styrenic block copolymers for biomaterial and drug delivery applications. Acta Biomater 2005; 1(1): 137-44.
24. Antony P, Puskas JE, Kontopoulou M. Investigation of the rheological and mechanical properties of a polystyrene-polyisobutylene-polystyrene triblock copolymer and its blends with polystyrene. Polym Eng Sci 2003; 43(1): 243-53.
25. th ed. USA: Wiley 1991; p. 198.
26. Storey RF, Chisholm BJ, Masse MA. Morphology and physical properties of poly(styrene-b-isobutylene-b-styrene) block copolymers. Polymer 1996; 37(14): 2925-38.
27. Strickler F, Richard R, McFadden S, et al. In vivo and in vitro characterization of poly(styrene-b-isobutylene-b-styrene) copolymer stent coatings for biostability, vascular compatibility and mechanical integrity. J Biomed Mater Res A 2010; 92(2): 773-82.
28. Gyor M, Fodor Z, Wang HC, Faust R. Polyisobutylene-based thermoplastic elastomers. I. Synthesis and characterization of poly-styrene-polysiobutylene-polystyrene triblock copolymers. J Mac-romol Sci Pure Appl Chem 1994; A31: 2055-65.
29. Pinchuk L, Pinchuk L, Pinchuk LS. US 5741331: Biostable elas-tomeric polymers having quaternary carbons, 1998.
30. Pinchuk L, Kahn J, Martin JB, Wilson GJ. Transactions of the World Biomaterials Congress 2001; 1452.
31. Stone GW, Ellis SG, Cox DA, et al. A polymer-based, paclitaxel-eluting stent in patients with coronary artery disease. N Engl J Med 2004; 350(3): 221-31.
32. Silber S. Paclitaxel-eluting stents: are they all equal? An analysis of six randomized controlled trials in de novo lesions of 3,319 patients. J Interv Cardiol 2003; 16(6): 485-90.
33. Russell ME. Comprehensive review of the polymer-based taxol release kinetics and animal data: insights into efficacy and toxicity. Transcatheter Cardiovascular Therapeutics (TCT) 2002. Washington, DC; 2002.
34. Steckel M, Richard R, Straumann P, Barry J. In vivo biostability of SIBS controlled release polymer in TAXUS drug eluting coronary stents. Paper presented at: Transactions of the Biomaterials in Regenerative Medicine Symposium. Philadelphia, PA; October 16-18, 2004.
35. Grube E, Silber S, Hauptmann KE, et al. TAXUS I: six- and twelve-month results from a randomized, double-blind trial on a slow-release paclitaxel-eluting stent for de novo coronary lesions. Circulation 2003; 107(1): 38-42.
36. Wise DL. Handbook of pharmaceutical controlled release technology. New York: Marcel Dekker 2000.
37. Saltzman WM. Controlled drug delivery systems. In: Saltzman WM, ed. Drug delivery: engineering principles for drug therapy. New York: Oxford University Press 2001; pp. 235-80.
38. Pre-market approval P070015 (FDA): Summary of safety and effectiveness data (SSED), XIENCE. July, 2008.
39. Ding N, Pacetti S, Tang F, Gada M, Roorda W. XIENCE(™) stent design and rationale. Intervent Cardiol 2009; 22(Suppl 1): 818-27.
40. Xu X, Rexer E, Tang E, Hsiao B, Rong L, Mao Y. Characterization of PVDF-HFP Copolymer and Model Coating of XIENCE V™ Drug Eluting Stent By Synchrotron. Transactions of the Soc. of Biomaterials Conference 2009; Paper No. 137.
41. Hayward JA, Chapman D. Biomembrane surfaces as models for polymer design: the potential for haemocompatibility. Biomaterials 1984; 5(3): 135-42.
42. von Segesser LK, Olah A, Leskosek B, Turina M. Coagulation patterns in bovine left heart bypass with phospholipid versus hepa-rin surface coating. ASAIO J 1993; 39(1): 43-6.
43. Hunter S, Angelini GD. Phosphatidylcholine-coated chest tubes improve drainage after open heart operation. Ann Thorac Surg 1993; 56(6): 1339-42.
44. Cumberland DC. The DivYsio Stent. In: Serruys PW, Kutryk MJB, Eds. Handbook of coronary stents. Dunitz 1998; pp. 203-212.
45. Campbell EJ, O'Byrne V, Stratford PW, et al. Biocompatible surfaces using methacryloylphosphorylcholine laurymethacrylate co-polymers. ASAIO J 1994; 40: 853-7.
46. Ishihara K, Aragaki R, Ueda T, Watenabe A, Nakabayashi N. Reduced thrombogenicity of polymers having phospholipid polar groups. J Biomed Mater Res 1990; 24(8): 1069-77.
47. Ishihara K, Oshida H, Endo Y, Ueda T, Watanabe A, Nakabayashi N. Hemocompatibility of human whole blood on polymers with a phospholipid polar group and its mechanism. J Biomed Mater Res 1992; 26(12): 1543-52.
48. Lewis AL, Cumming ZL, Goreish HH, Kirkwood LC, Tolhurst LA, Stratford PW. Crosslinkable coatings from phosphorylcholine-based polymers. Biomaterials 2001; 22(2): 99-111.
49. Lewis AL, Stratford PW. Phosphorylcholine-coated stents. J Long Term Eff Med Implants 2002; 12(4): 231-250.
50. Lewis AL, Tolhurst LA, Stratford PW. Analysis of a phosphoryl-choline-based polymer coating on a coronary stent pre- and post-implantation. Biomaterials 2002; 23(7): 1697-706.
51. Malik N, Gunn J, Shepherd L, Crossman DC, Cumberland DC, Holt CM. Phosphorylcholine-coated stents in porcine coronary arteries: in vivo assessment of biocompatibility. J Invasive Cardiol 2001; 13(3): 193-201.
52. Kuiper KK, Robinson KA, Chronos NA, Cui J, Palmer SJ, Nordre-haug JE. Phosphorylcholine-coated metallic stents in rabbit iliac and porcine coronary arteries. Scand Cardiovasc J 1998; 32(5): 261-8.
53. Whelan DM, van der Giessen WJ, Krabbendam SC, et al. Biocom-patibility of phosphorylcholine coated stents in normal porcine coronary arteries. Heart 2000; 83(3): 338-45.
54. Garcia-Touchard A, Burke SE, Toner JL, Cromack K, Schwartz RS. Zotarolimus-eluting stents reduce experimental coronary artery neointimal hyperplasia after 4 weeks. Eur Heart J 2006; 27(8): 988-93.
55. Fajadet J, Wijns W, Laarman GJ, et al. Randomized, double-blind, multicenter study of the Endeavor zotarolimus-eluting phosphoryl-choline-encapsulated stent for treatment of native coronary artery lesions: clinical and angiographic results of the ENDEAVOR II trial. Circulation 2006; 114(8): 798-806.
56. Lewis AL, Furze JD, Small S, et al. Long-term stability of a coronary stent coating post-implantation. J Biomed Mater Res 2002; 63(6): 699-705.
57. Leon MB. Endeavor IV: A randomized comparison of a zotarolimus-eluting stent and a paclitaxel-eluting stent in patients with coronary artery disease. Transcatheter Cardiovascular Therapeutics 2007. Washington, DC 2007.
58. Burke SE, Kuntz RE, Schwartz LB. Zotarolimus (ABT-578) eluting stents. Adv Drug Deliv Rev 2006; 58(3): 437-46.
59. Lewis AL, Vick TA, Collias AC, et al. Phosphorylcholine-based polymer coatings for stent drug delivery. J Mater Sci Mater Med 2001; 12(10-12): 865-70.
60. Udipi K, Chen M, Cheng P, et al. Development of a novel biocom-patible polymer system for extended drug release in a next-generation drug-eluting stent. J Biomed Mater Res A 2008; 85(4): 1064-71.
61. Hezi-Yamit A, Sullivan C, Wong J, et al. Impact of polymer hy-drophilicity on biocompatibility: implication for DES polymer design. J Biomed Mater Res A 2009; 90(1): 133-41.
62. van Krevlen DW. Properties of polymers: their estimation and correlation with chemical structures. New York: Elsevier Scientific; 1976.
63. Carter AJ, Melder RJ, Udipi K, Ozdil F, Virmani R, Wilcox JN. In vivo performance of a novel co-polymer system for the extended release of zotarolimus in a next generation durg eluting stent. Tran-scatheter Cardiovascular Therapeutics (TCT) 2006. Washington, DC 2006.
64. Meredith IT, Worthley S, Whitbourn R, et al. Clinical and angi-ographic results with the next-generation Resolute™ stent system: a prospective, multicenter, first-in-human trial. JACC Cardiovasc Interv 2009; 2(10): 977-85.
65. Brannon-Peppas L. Polymers in controlled drug delivery. Medical Device and Diagnostic Industry 1997.
66. Langer R. Biomaterials and biomedical engineering. Chem Eng Sci 1995; 50(24): 4109-21.
67. Gopferich A. Mechanisms of polymer degradation and erosion. Biomaterials 1996; 17(2): 103-14.
68. von Burkersroda F, Schedl L, Gopferich A. Why degradable polymers undergo surface erosion or bulk erosion. Biomaterials 2002; 23(21): 4221-31.
69. Uhrich KE, Cannizzaro SM, Langer RS, Shakesheff KM. Polymeric systems for controlled drug release. Chem Rev 1999; 99(11): 3181-98.
70. Tamada J, Langer R. The development of polyanhydrides for drug delivery applications. J Biomater Sci Polym Ed 1992; 3(4): 315-53.
71. Staubli A, Mathiowitz E, Lucarelli M, Langer R. Characterization of hydrolytically degradable amino acid containing poly(anhydride-co-imides). Macromolecules 1991; 24: 2283-90.
72. Anastasiou T, Uhrich K. Novel polyanhydrides with enhanced thermal and solubility properties. Macromolecules 2000; 33: 6217-21.
73. Schwach-Abdekkaoui K, Heller J, Gurny R. Hydrolysis and erosion studies of autocatalyzed poly(orthoesters) containing lactoyl-lactyl acid dimers. Macromolecules 1999; 32: 301-7.
74. Middleton JC, Tipton AJ. Synthetic biodegradable polymers as medical devices. Med Plastics Biomater 1998.
75. Pulapura S, Kohn J. Tyrosine-derived polycarbonates: backbone-modified pseudo-poly (amino acids) designed for biomedical applications. Biopolymers 1992; 32(4): 411-7.
76. Ertel SI, Kohn J. Evaluation of a series of tyrosine-derived polycarbonates as degradable biomaterials. J Biomed Mater Res 1994; 28(8): 919-30.
77. Pulapura S, Li C, Kohn J. Structure-property relationships for the design of polyiminocarbonates. Biomaterials 1990; 11(9): 666-78.
78. Fiordeliso J, Bron S, Kohn J. Design, synthesis, and preliminary characterization of tyrosine-containing polyarylates: new biomaterials for medical applications. J Biomater Sci Polym Ed 1994; 5(6): 497-510.
79. Andrianov A, Payne L, Visscher K, Allcock HR, Langer R. Hydro-lytic degradation of ionically cross-linked polyphosphazene micro-spheres. J Appl Polym Sci 1994; 53: 497-510.
80. Ibim SE, Ambrosio AM, Kwon MS, El-Amin SF, Allcock HR, Laurencin CT. Novel polyphosphazene/poly(lactide-co-glycolide) blends: miscibility and degradation studies. Biomaterials 1997; 18(23): 1565-9.
81. Lemmouchi Y, Schacht E, Dejardin S. Biodegradable poly[(amino acid ester) phosphazenes for biomedical applications. J Bioactive Comp Polym 1998; 13: 4-18.
82. van der Giessen WJ, Lincoff AM, Schwartz RS, et al. Marked inflammatory sequelae to implantation of biodegradable and non-biodegradable polymers in porcine coronary arteries. Circulation 1996; 94(7): 1690-7.
83. Middleton JC, Tipton AJ. Synthetic biodegradable polymers as orthopedic devices. Biomaterials 2000; 21(23): 2335-2346.
84. Daemen J, Serruys PW. Drug-eluting stent update 2007: part I. A survey of current and future generation drug-eluting stents: meaningful advances or more of the same? Circulation 2007; 116(3): 316-28.
85. O'Brien B, Carroll W. The evolution of cardiovascular stent materials and surfaces in response to clinical drivers: a review. Acta Biomater 2009; 5(4): 945-58.
86. Jeong B, Bae YH, Lee DS, Kim SW. Biodegradable block copoly-mers as injectable drug-delivery systems. Nature 1997; 388(6645): 860-2.
87. Berges R, Bello U. Effect of a new leuprorelin formulation on testosterone levels in patients with advanced prostate cancer. Curr Med Res Opin 2006; 22(4): 649-55.
88. Southard GL, Dunn RL, Garrett S. The drug delivery and biomate-rial attributes of the ATRIGEL technology in the treatment of periodontal disease. Expert Opin Investig Drugs 1998; 7(9): 1483-91.
89. Li S. Hydrolytic degradation characteristics of aliphatic polyesters derived from lactic and glycolic acids. J Biomed Mater Res 1999; 48(3): 342-53.
90. Lu L, Garcia CA, Mikos AG. In vitro degradation of thin poly(DL-lactic-co-glycolic acid) films. J Biomed Mater Res 1999; 46(2): 236-44.
91. Siegel SJ, Kahn JB, Metzger K, Winey KI, Werner K, Dan N. Effect of drug type on the degradation rate of PLGA matrices. Eur J Pharm Biopharm 2006; 64(3): 287-93.
92. Loo JS, Ooi CP, Boey FY. Degradation of poly(lactide-co-glycolide) (PLGA) and poly(L-lactide) (PLLA) by electron beam radiation. Biomaterials 2005; 26(12): 1359-67.
93. Shive MS, Anderson JM. Biodegradation and biocompatibility of PLA and PLGA microspheres. Adv Drug Deliv Rev 1997; 28(1): 5-24.
94. Jain RA. The manufacturing techniques of various drug loaded biodegradable poly(lactide-co-glycolide) (PLGA) devices. Biomaterials 2000; 21(23): 2475-90.
95. Abizaid A. Next generation metallic stents. American College of Cardiology Conference 2009.
96. Grube E. JACTAX Clinical Trial: Interim 9 Month Results. Tran-scatheter Cardiovascular Therapeutics (TCT) Conference. Washington, DC 2008.
97. Gambhir D. The Sahajanand Infinnium Bioabsorbable Paclitaxel Eluting Stent. Transcatheter Cardiovascular Therapeutics (TCT) Conference. Washington, DC 2006.
98. Byrne RA, Kastrati A, Kufner S, et al. Randomized, non-inferiority trial of three limus agent-eluting stents with different polymer coatings: the Intracoronary Stenting and Angiographic Results: Test Efficacy of 3 Limus-Eluting Stents (ISAR-TEST-4) Trial. Eur Heart J 2009; 30(20): 2441-9.
99. http://www.innocore.nl/polymers.
100. Granada J. The Orbus-Neich EPC Coated Bioabsorbable Polymer Sirolimus Eluting Stent Program. Transcatheter Cardiovascular Therapeutics (TCT) Conference. San Francisco, CA 2009.